METTL3 and acute myeloid leukemia: It has been shown that METTL3 acts as an oncogene in AML and its activity depends on interaction with the CAAT-box binding protein CEBPZ, which promotes METTL3 localisation to chromatin and induces m6A modification on specific mRNA transcripts such as SP1 and SP2 (13).